Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Scientist Publishes Data on the Pre-Clinical Efficacy of AB569 in Killing of Drug Resistant Bacteria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"University of Cincinnati","sponsor":"Arch Biopartners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arch Biopartners Enters Exclusive License Agreement with the University of Cincinnati for AB569 Topical Wound Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARCH Publishes Paper Showing Pre-Clinical Efficacy of AB569 Against Multi-Drug Resistant Acinetobacter Baumannii and Acinetobacter spp","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Salud Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kane Biotech Announces First Distribution Agreement for its Coactiv+\u2122 Antimicrobial Hydrogel","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved"},{"orgOrder":0,"company":"ProgenaCare Global","sponsor":"Kane Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$0.5 million","newsHeadline":"Kane Biotech Announces Distribution Agreement with ProgenaCare Global for its Coactiv+\u2122 Antimicrobial Wound Gel","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok\u00ae Phase 3 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Rising Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rising Pharmaceuticals Launches Edetate Calcium Disodium Injection, an Important Antidote Treatment to Address Lead Poisoning","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Approved"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Venus Remedies Expands Reach with the Launch of Elores in Ecuador","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kane Biotech and ProgenaCare Global Launch Newly Rebranded Revyve\u2122 Antimicrobial Wound Gel at Advanced Wound Care Fall Forum","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"November 2023","url1":"","url2":"","graph1":"Podiatry","graph2":"Approved"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok\u00ae Therapeutic to Salvage Catheters","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals for 62-33-9

    Menu

    62-33-9

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Citius Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters

              Details:

              Mino-Lok (MLT) is a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.

              Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol

              Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 02, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kane Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kane Biotech and ProgenaCare Global Launch Newly Rebranded Revyve™ Antimicrobial Wound Gel at Advanced Wound Care Fall Forum

              Details:

              revyve™ Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult populations.

              Lead Product(s): Edetate Calcium Disodium,Citric Acid

              Therapeutic Area: Podiatry Product Name: Revye

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 02, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Venus Remedies

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Venus Remedies Expands Reach with the Launch of Elores in Ecuador

              Details:

              Elores, a cutting-edge antibiotic novel combination of Ceftriaxone (third generation beta-lactam cephalosporin), Sulbactam (beta-lactamase inhibitor) and Disodium EDTA (Class 1 Antibiotic Resistance Breaker) for complicated urinary tract infections.

              Lead Product(s): Ceftriaxone,Edetate Calcium Disodium,Sulbactam

              Therapeutic Area: Infections and Infectious Diseases Product Name: Elores

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Citius Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial

              Details:

              Mino-Lok (MLT), a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.

              Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol

              Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Rising Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Rising Pharmaceuticals Launches Edetate Calcium Disodium Injection, an Important Antidote Treatment to Address Lead Poisoning

              Details:

              Edetate calcium disodium for injection is a prescription medicine, used for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.

              Lead Product(s): Edetate Calcium Disodium

              Therapeutic Area: Pharmacology/Toxicology Product Name: Edetate Calcium Disodium-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Citius Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering

              Details:

              The net proceeds will be used to fund the company's pre-clinical and clinical development of its product candidates, including Mino-Lok® (minocycline), an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and CLABSIs.

              Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol

              Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: H.C. Wainwright & Co.

              Deal Size: $15.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering May 08, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ProgenaCare Global

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kane Biotech Announces Distribution Agreement with ProgenaCare Global for its Coactiv+™ Antimicrobial Wound Gel

              Details:

              Under the agreement, ProgenaCare will commercialize coactiv+ (disodium EDTA) Antimicrobial Wound Gel in the U.S. wound care market. The coactiv+ is a combination of Kane’s patented coactiv+™ technology and PHMB, paired with a non-ionic pluronic surfactant.

              Lead Product(s): Edetate Calcium Disodium,Sodium Citrate

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Coactiv+

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Kane Biotech

              Deal Size: Undisclosed Upfront Cash: $0.5 million

              Deal Type: Agreement April 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kane Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kane Biotech Announces First Distribution Agreement for its Coactiv+™ Antimicrobial Hydrogel

              Details:

              The coactiv+™ (disodium EDTA) Antimicrobial Hydrogel is a combination of Kane’s patented coactiv+™ antibiofilm technology and PHMB in a thermo-reversible gel.

              Lead Product(s): Edetate Calcium Disodium,Sodium Citrate

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Coactiv+

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Salud Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 04, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              University of Cincinnati

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Arch Biopartners Enters Exclusive License Agreement with the University of Cincinnati for AB569 Topical Wound Treatment

              Details:

              AB569 has been shown to kill multi-drug resistant (MDR) Gram-negative (G-) bacteria such as Pseudomonasaeruginosa, that is responsible for over half of all severe burn infections, and identified as a “major pathogen” by the Centers for Disease Control and Prevention.

              Lead Product(s): Acidified nitrite,Edetate Calcium Disodium

              Therapeutic Area: Infections and Infectious Diseases Product Name: AB569

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Arch Biopartners

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement March 24, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Arch Biopartners

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ARCH Publishes Paper Showing Pre-Clinical Efficacy of AB569 Against Multi-Drug Resistant Acinetobacter Baumannii and Acinetobacter spp

              Details:

              Paper published in the journal PloS One demonstrated that AB569 kills multi-drug resistant strains of Acinetobacter baumannii and Acinetobacter spp. bacteria.

              Lead Product(s): Acidified nitrite,Edetate Calcium Disodium

              Therapeutic Area: Infections and Infectious Diseases Product Name: AB569

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 04, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Ofichem Edetate Calcium Disodium
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Close
              4
              Post Enquiry
              POST ENQUIRY